Roivant Sciences Ltd. (ROIV)
Data as of , from SEC Form 4 filings.
See up to 3 months of ROIV. The 7-day demo opens the 1M and 3M ranges and puts ROIV on your watchlist.
Start 7-day demoLatest ROIV insider trades
About Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- LONDON
- 721
- 2021
- XNAS
ROIV Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 18 | 1,647,800 | $59.83M |
| Grant or award | 15 | 95,233 | |
| Option exercise | 23 | 3,275,500 | |
ROIV insider transactions (Form 4)
116141 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Richard Pulik - Officer | Tax withholding / forfeiture | Common Shares | 1,000 footnote F1 | $27.15 | $27K | |
| ||||||
| Eric Venker - Officer | Tax withholding / forfeiture | Common Shares | 7,051 footnote F1 | $27.15 | $191K | |
| ||||||
| Frank Torti - Officer | Option exercise | Common Shares | 1,400,000 | $3.85 | $5.39M | |
| Frank Torti - Officer | Option exercise | Common Shares | 1,012,610 | $3.85 | $3.90M | |
| Frank Torti - Officer | Option exercise | Common Shares | 587,390 | $3.85 | $2.26M | |
| Frank Torti - Officer | Option exercise | Stock Option (Right to Buy) | 1,400,000 | $0.00 | - | |
| Frank Torti - Officer | Open-market sale | Common Shares | 1,400,000 | $27.42 footnote F1,F2 | $38.39M | |
| Frank Torti - Officer | Open-market sale | Common Shares | 1,012,610 | $27.15 footnote F1,F3 | $27.49M | |
| Frank Torti - Officer | Open-market sale | Common Shares | 587,390 | $27.51 footnote F1,F4 | $16.16M | |
| Frank Torti - Officer | Option exercise | Stock Option (Right to Buy) | 1,012,610 | $0.00 | - | |
| Frank Torti - Officer | Option exercise | Stock Option (Right to Buy) | 587,390 | $0.00 | - | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 | $26.49 footnote F1 | $5.30M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
| Keith S. Manchester | Open-market sale | Common Shares | 425,000 | $26.67 | $11.33M | |
| Keith S. Manchester | Open-market sale | Common Shares | 150,000 | $26.72 | $4.01M | |
| Keith S. Manchester | Open-market sale | Common Shares | 275,000 | $26.76 | $7.36M | |
| Keith S. Manchester | Open-market sale | Common Shares | 150,784 | $26.49 | $3.99M | |
| Keith S. Manchester | Open-market sale | Common Shares | 225,000 | $26.50 | $5.96M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 425,000 | $26.67 | $11.33M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 150,000 | $26.72 | $4.01M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 275,000 | $26.76 | $7.36M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 150,784 | $26.49 | $3.99M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 225,000 | $26.50 | $5.96M | |
| QVT Financial LP | Open-market sale | Common Shares | 425,000 | $26.67 | $11.33M | |
| QVT Financial LP | Open-market sale | Common Shares | 150,000 | $26.72 | $4.01M | |
| QVT Financial LP | Open-market sale | Common Shares | 275,000 | $26.76 | $7.36M | |
| QVT Financial LP | Open-market sale | Common Shares | 150,784 | $26.49 | $3.99M | |
| QVT Financial LP | Open-market sale | Common Shares | 225,000 | $26.50 | $5.96M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 651,558 | $12.68 | $8.26M | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 651,558 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 339,441 | $26.47 footnote F1,F2 | $8.99M | |
| Mayukh Sukhatme - Officer | Other | Common Shares | 312,117 footnote F3 | $26.47 footnote F1 | $8.26M | |
| ||||||
| James C. Momtazee | Grant or award | Common Shares | 609 footnote F1 | $0.00 footnote F1 | - | |
| James C. Momtazee | Tax withholding / forfeiture | Common Shares | 122 footnote F2 | $22.98 | $3K | |
| ||||||
| Ilan Oren | Grant or award | Common Shares | 1,164 footnote F1 | $0.00 footnote F1 | - | |
| Ilan Oren | Tax withholding / forfeiture | Common Shares | 124 footnote F2 | $22.98 | $3K | |
| ||||||
| Melissa B, Epperly | Grant or award | Common Shares | 815 footnote F1 | $0.00 footnote F1 | - | |
| Melissa B, Epperly | Tax withholding / forfeiture | Common Shares | 54 footnote F2 | $22.98 | $1K | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 | $21.92 footnote F1 | $4.38M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 748,358 | $12.68 | $9.49M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 2,449,877 | $12.68 | $31.06M | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 311,873 | $21.74 footnote F1,F2 | $6.78M | |
| Mayukh Sukhatme - Officer | Other | Common Shares | 436,485 footnote F4 | $21.74 footnote F1 | $9.49M | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 1,018,995 | $21.71 footnote F1,F3 | $22.12M | |
| Mayukh Sukhatme - Officer | Other | Common Shares | 1,430,882 footnote F4 | $21.71 footnote F1 | $31.06M | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 748,358 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 2,449,877 | $0.00 | - | |
| ||||||
| Frank Torti - Officer | Grant or award | Common Shares | 175,380 | $22.45 footnote F1 | $3.94M | |
| Frank Torti - Officer | Other | Common Shares | 64,891 | $22.47 footnote F2,F3 | $1.46M | |
| Frank Torti - Officer | Gift | Common Shares | 110,489 | $0.00 | - | |
| ||||||
| Richard Pulik - Officer | Option exercise | Common Shares | 260,000 | $3.85 | $1.00M | |
| Richard Pulik - Officer | Open-market sale | Common Shares | 260,000 | $22.45 footnote F1,F2 | $5.84M | |
| Richard Pulik - Officer | Open-market sale | Common Shares | 146,731 | $22.39 footnote F1,F3 | $3.29M | |
| Richard Pulik - Officer | Option exercise | Stock Option (Right to Buy) | 260,000 | $0.00 | - | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 313,841 | $3.85 | $1.21M | |
| Eric Venker - Officer | Option exercise | Common Shares | 117,848 | $3.85 | $454K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 footnote F1 | $22.45 footnote F2,F3 | $4.49M | |
| Eric Venker - Officer | Open-market sale | Common Shares | 75,000 footnote F1 | $22.53 footnote F2,F4 | $1.69M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 313,841 | $0.00 | - | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 117,848 | $0.00 | - | |
| ||||||
| Richard Pulik - Officer | Tax withholding / forfeiture | Common Shares | 2,129 footnote F1 | $22.41 | $48K | |
| ||||||
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 59,513 | $12.68 | $755K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 26,831 | $23.09 footnote F1 | $620K | |
| Mayukh Sukhatme - Officer | Other | Common Shares | 32,682 footnote F2 | $23.09 footnote F1 | $755K | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 59,513 | $0.00 | - | |
| ||||||
| Daniel Allen Gold | Open-market sale | Common Shares | 275,000 | $22.93 | $6.31M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 642,282 | $23.08 | $14.82M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 432,718 | $23.05 | $9.97M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 155,076 | $23.02 | $3.57M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 189,538 | $23.17 | $4.39M | |
| Keith S. Manchester | Open-market sale | Common Shares | 275,000 | $22.93 | $6.31M | |
| Keith S. Manchester | Open-market sale | Common Shares | 642,282 | $23.08 | $14.82M | |
| Keith S. Manchester | Open-market sale | Common Shares | 432,718 | $23.05 | $9.97M | |
| Keith S. Manchester | Open-market sale | Common Shares | 155,076 | $23.02 | $3.57M | |
| Keith S. Manchester | Open-market sale | Common Shares | 189,538 | $23.17 | $4.39M | |
| QVT Financial LP | Open-market sale | Common Shares | 275,000 | $22.93 | $6.31M | |
| QVT Financial LP | Open-market sale | Common Shares | 642,282 | $23.08 | $14.82M | |
| QVT Financial LP | Open-market sale | Common Shares | 432,718 | $23.05 | $9.97M | |
| QVT Financial LP | Open-market sale | Common Shares | 155,076 | $23.02 | $3.57M | |
| QVT Financial LP | Open-market sale | Common Shares | 189,538 | $23.17 | $4.39M | |
 Matthew Gline - Officer | Option exercise | Common Shares | 234,096 | $4.06 | $950K | |
| Matthew Gline - Officer | Option exercise | Common Shares | 1,363,711 | $12.68 | $17.29M | |
| Matthew Gline - Officer | Option exercise | Common Shares | 2,272,852 | $12.68 | $28.82M | |
| Matthew Gline - Officer | Open-market sale | Common Shares | 230,357 | $21.68 footnote F1 | $4.99M | |
| Matthew Gline - Officer | Other | Common Shares | 3,739 footnote F2 | $21.68 footnote F1 | $81K | |
| Matthew Gline - Officer | Open-market sale | Common Shares | 566,116 | $21.68 footnote F1 | $12.27M | |
| Matthew Gline - Officer | Other | Common Shares | 797,595 footnote F2 | $21.68 footnote F1 | $17.29M | |
| Matthew Gline - Officer | Open-market sale | Common Shares | 943,527 | $21.68 footnote F1 | $20.46M | |
| Matthew Gline - Officer | Other | Common Shares | 1,329,325 footnote F2 | $21.68 footnote F1 | $28.82M | |
| Matthew Gline - Officer | Option exercise | Stock Option (Right to Buy) | 234,096 | $0.00 | - | |
| Matthew Gline - Officer | Option exercise | Stock Option (Right to Buy) | 1,363,711 | $0.00 | - | |
| Matthew Gline - Officer | Option exercise | Stock Option (Right to Buy) | 2,272,852 | $0.00 | - | |
| ||||||
| Richard Pulik - Officer | Tax withholding / forfeiture | Common Shares | 1,235 footnote F1 | $20.27 | $25K | |
| ||||||
| Eric Venker - Officer | Tax withholding / forfeiture | Common Shares | 7,051 footnote F1 | $20.27 | $143K | |
| ||||||
| Daniel Allen Gold | Open-market sale | Common Shares | 150,000 | $20.20 | $3.03M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 125,000 | $20.16 | $2.52M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 175,000 | $20.24 | $3.54M | |
| Daniel Allen Gold | Open-market sale | Common Shares | 850,000 | $20.25 | $17.21M | |
| QVT Financial LP | Open-market sale | Common Shares | 150,000 | $20.20 | $3.03M | |
| QVT Financial LP | Open-market sale | Common Shares | 125,000 | $20.16 | $2.52M | |
| QVT Financial LP | Open-market sale | Common Shares | 175,000 | $20.24 | $3.54M | |
| QVT Financial LP | Open-market sale | Common Shares | 850,000 | $20.25 | $17.21M | |
| Keith S. Manchester | Open-market sale | Common Shares | 125,000 | $20.16 | $2.52M | |
| Keith S. Manchester | Open-market sale | Common Shares | 175,000 | $20.24 | $3.54M | |
| Keith S. Manchester | Open-market sale | Common Shares | 850,000 | $20.25 | $17.21M | |
| Keith S. Manchester | Open-market sale | Common Shares | 150,000 | $20.20 | $3.03M | |
 Vivek Ramaswamy - 10% Owner | Open-market sale | Common Shares | 539,650 | $20.51 footnote F3 | $11.07M | |
| Vivek Ramaswamy - 10% Owner | Open-market sale | Common Shares | 287,283 | $20.81 footnote F1 | $5.98M | |
| Vivek Ramaswamy - 10% Owner | Open-market sale | Common Shares | 1,027,670 | $20.33 footnote F2 | $20.89M | |
| ||||||
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $20.22 | $4.04M | |
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 | $20.22 footnote F1 | $4.04M | |
| ||||||
| Melissa B, Epperly | Grant or award | Common Shares | 1,056 footnote F1 | $0.00 footnote F1 | - | |
| ||||||
See every ROIV filing on record
These pages show the latest 90 of 141 Form 4 filings on record. The 7-day demo shows all 141, and sign-up brings you back to this table.
Item 5.07, 9.01
Item 7.01, 9.01
Item 8.01, 9.01
Item 7.01, 9.01
Recent ROIV Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Venker Eric | Officer | 200,000 | $7.32M | View on EDGAR | |
| MELISSA EPPERLY | Director | 22,688 |
Stock trades in ROIV disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Lisa C. McClainRepublican, MI-09 | Sale |
ROIV insider trading FAQ
What is the latest insider trade for ROIV?
Roivant Sciences Ltd. (ROIV) had 30 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for ROIV runs to 141 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ROIV stock?
No insider purchases of ROIV were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling ROIV stock?
18 insider sales of ROIV were filed in the last 90 days, totaling $59.83M.
Where can I see ROIV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ROIV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Melissa B, Epperly view on EDGAR
- - Matthew Gline view on EDGAR
- - Frank Torti view on EDGAR
- - Mayukh Sukhatme view on EDGAR
- - Eric Venker view on EDGAR
- - Jennifer Humes view on EDGAR
- - Richard Pulik view on EDGAR
- - Keith S. Manchester view on EDGAR
- - Daniel Allen Gold view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ROIV's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ROIV with a 7-day demo
- ROIV on your watchlist
- Every ROIV Form 4 filing on record
- Up to 3 months of ROIV price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
